2[1]Jones, HW. Endometrial hyperplasia. In: Jones HW, Wentz AC & Burnett LS, editors.Novak's Textbook of Gynecology, 11th ed. Baltimore: Williams & Wilkins, 1988, p716～27.
3[2]Livingstone M & Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update,2002, 8:60～7.
4[3]Bergeron C, Nogales FF, Masseroli Abeler V, Duvillard P, Muller-Holzner E, Pickartz H &Wells M. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol, 1999, 23(9):1 102～8.
5[4]Moller B, Rasmussen C, Lindblom B & Olovsson M. Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle. Mol Hum Reprod, 2001, 7(1): 65 ～ 72.
6[5]Kaku T, Kamura T, Kinukawa N, Kobayashi H, Sakai K, Tsuruchi N, Saito T, Kawauchi S,Tsuneyoshi M & Nakano H. Angiogenesis in endometrial carcinoma. Cancer, 1997, 80: 741～7.
7[6]Greb RR, Heikinheimo O &Williams RF. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum Reprod, 1997, 12(6):1 280～92.
8[7]Charnock-Jones DS, Sharkey AM, Rajput-Williams J Burch D, Schofield JP, Fountain SA,Boocook CA & Smith SK. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod, 1993, 48(5): 1 120～8.
9[8]Fujishita A, Hasuo A, Khan KN, Masuzaki H, Nakashima H & Ishimaru T. Immunohistochemical study of angiogenicfactors in endometrium and endometriosis. Gynecol Obstet Invest, 1999, 48 (Suppl 1):36～44.
10[9]Lau TM, Affandi B & Rogers PA. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium. Mol Hum Reprod, 1999, 5(1):57～63.
